NCT06279026 - UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

July 1, 2027

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

UTAA17 Injection

After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.

Trial Locations (1)

215000

RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou